12 Results for "

GBM U87

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "GBM U87" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-N3001
CAS No.: 957-66-4
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .
loading...
    loading...
Cat. No.: HY-168708
CAS No.: 3099231-05-4
Research Areas:  

Cancer

AH2-14c is an inhibitor for DNA demethylase ALKBH2. AH2-14c inhibits the cell viability (IC50 is 4.56 µM) and migration of GBM U87. AH2-14c regulates the expression of apoptosis-related genes, and induces apoptosis in GBM U87 cell .
loading...
    loading...
Cat. No.: HY-124813
CAS No.: 2083618-79-3
Purity:  99.29%
Synonyms: 113B7
Target:  

FAK EGFR MMP NF-κB SDCBP

Research Areas:  

Cancer

PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-173066
CAS No.: 3048196-52-4
Research Areas:  

Cancer

NU227326 is a blood-brain barrier penetrant IDO1 PROTAC degrader, with a DC50 of 4.5 nM in HiBiT degradation assays. NU227326 degrades IDO1 in U87 and GBM43 cells, with DC50 values of 7.1 nM and 11.8 nM, respectively (WB assays). NU227326 is applicable to research related to glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer .
loading...
    loading...
Cat. No.: HY-155888
CAS No.: 3057089-47-8
Purity:  98.41%
Target:  

SWI/SNF Complex

Research Areas:  

Cancer

IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. IV-255 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-255 inhibits the invasiveness of GBM cells. IV-255 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
loading...
    loading...
Cat. No.: HY-125964
CAS No.: 1453835-43-2
Target:  

Survivin

Research Areas:  

Cancer

LLP-3 is a potent Survivin inhibitor that disrupts the Survivin-Ran interaction in cancer cells. LLP-3 can be used in the research of Glioblastoma multiforme (GBM) .
loading...
    loading...
Cat. No.: HY-147409
CAS No.: 2075750-05-7
Target:  

CDK

Research Areas:  

Cancer

Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .
loading...
    loading...
Cat. No.: HY-161256
CAS No.: 2770273-12-4
Research Areas:  

Cancer

Tubulin inhibitor 41 (Compd D19), a promising anti-GBM (glioblastoma) lead compound and tublin inhibitor with BBB permeability, induces G2/M phase arrest, resulted in cell apoptosis and inhibits the migration of U87 cells .
loading...
    loading...
Cat. No.: HY-157168
Target:  

Trk Receptor

Research Areas:  

Neurological Disease

TrkA-IN-6 (compound R48) is a hydrazone-like, selective inhibitor of tropomyosin kinase type A receptor kinase (TrkA). TrkA-IN-6 exhibited a higher cytotoxic effect on U87 GBM cells than Temozolomide (HY-17364), with an IC50 of 68.99 μM .
loading...
    loading...
Cat. No.: HY-P11029
Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

CES (CESPLLSEC) is a homing peptide targeting Synaptosomal associated protein 25 (SNAP25). CES specifically homes in intracranial U87MG and the WT-glioblastoma (GBM) model. CES can be used as a targeting peptide for drug delivery for cancers research .
loading...
    loading...
Cat. No.: HY-155889
Target:  

SWI/SNF Complex

Research Areas:  

Cancer

IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
loading...
    loading...
Cat. No.: HY-149696
CAS No.: 2387927-74-2
IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research .
loading...
    loading...
  • 1